{"prompt": "['Novartis', 'Confidential', 'Page 41', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '8.3.2.2 Quality of Life (SNOT-22)', 'For this study, the SNOT-22 questionnaire (listed in Section 16.5) will be used to assess any', 'improvement in the patients quality of life. The questionnaire consists of 22 questions relating', 'to various quality of life indicators and answers are scored from 0 (no problem) to 5 (problem', 'as bad as it can be) with questions relating to the patients experience in the previous 2 weeks.', 'The test will be self-administered by the patient via a tablet computer at the clinic visits outlined', 'in Table 8-1 and takes only a few minutes to complete. The final outcome is a total score from', '0 to 110.', '8.3.3', 'Smell (UPSIT)', 'For this study, any change in the patients sense of smell will be assessed using the University', 'of Pennsylvania Smell Identification Test. The test comprises of a kit which will be supplied to', 'sites. The test includes 4 workbooks, each of which contains 10 microencapsulated (scratch and', 'sniff) odors with forced choice responses accompanying each test item. The sites will also be', 'supplied with the relevant instruction manual and scoring key.', 'The test is administered at the clinic visits and usually takes 10-15 minutes to complete. The', 'result is a score out of 40 and this will be captured within the Clinical Database by the site', 'personnel.', '8.3.4', 'Appropriateness of efficacy assessments', 'The efficacy assessments outlined above are deemed to be sufficient for the objectives of the', 'study.', '8.4', 'Safety', 'Safety assessments are specified below with the assessment schedule detailing when each', 'assessment is to be performed.', 'For details on AE collection and reporting, refer to AE section.', 'Table 8-3', 'Physical Assessments', 'Assessment', 'Specification', 'Physical', 'A complete physical examination will include the examination of general appearance,', 'examination', 'skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back,', 'lymph nodes, extremities, vascular, and neurological. If indicated based on medical', 'history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be', 'performed.', 'Information for all physical examinations must be included in the source documentation at', 'the study site. Clinically relevant findings that are present prior to signing informed', 'consent must be recorded on the appropriate CRF that captures medical history.', 'Significant findings made after first administration of investigational drug which meet the', 'definition of an Adverse Event must be recorded as an adverse event.']['Novartis', 'Confidential', 'Page 42', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Assessment', 'Specification', 'Vital signs', 'Vital signs include blood pressure and pulse measurements. After the subject has been', 'sitting for five minutes, with back supported and both feet placed on the floor, systolic and', 'diastolic blood pressure will be measured three times using an automated validated', 'device, e.g. OMRON, with an appropriately sized cuff. The repeat sitting measurements', 'will be made at 1 - 2 minute intervals and the mean of the three measurements will be', \"used. In case the cuff sizes available are not large enough for the subject's arm\", 'circumference, a sphygmomanometer with an appropriately sized cuff may be used.', 'Height and', 'Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) in indoor', 'weight', 'clothing, but without shoes) will be measured.', '8.4.1', 'Laboratory evaluations', 'Samples for safety will be collected as per the assessment schedule in Table 8-1 A central', 'laboratory will be used for analysis of all specimens detailed in this section. Details on the', 'collections, shipment of samples and reporting of results by the central laboratory are provided', 'to Investigators in the laboratory manual.', 'Details on clinically notable laboratory findings are defined in Section 16.1', 'Table 8-4', 'Laboratory Assessments', 'Test Category', 'Test Name', 'Hematology', 'Hematocrit, Hemoglobin, MCH, MCHC, MCV, Platelets, Red blood cells, White blood', 'cells, Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils,', 'Other).', 'Clinical Chemistry', 'Albumin, Alkaline phosphatase, ALT, AST, Gamma-glutamyl-transferase (GGT),', 'Lactate dehydrogenase (LDH), Calcium, Magnesium, Phosphorus, Chloride, Sodium,', 'Potassium, Creatinine, Creatine kinase, CK-MB and Troponin I (in response to CK', 'results outside of the normal range), HbA1c (collected at Screening visit and EOT', 'only), Direct Bilirubin, Total Bilirubin, Total Cholesterol, Total Protein, Triglycerides,', 'Blood Urea Nitrogen (BUN) or Urea, Uric Acid, Amylase, Lipase, Glucose.', 'Urinalysis', 'Microscopic Panel (Red Blood Cells, White Blood Cells, Casts, Crystals, Bacteria,', 'Epithelial cells) - if required.', 'Macroscopic Panel (Dipstick) (Color, Bilirubin, Blood, Glucose, Ketones, Leukocytes', 'esterase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen)', 'Urine chemistry and microscopic examination of the urine will be performed by the', 'central laboratory as delineated in Section 10.2.2 \"Renal Safety Monitoring\"', 'and Section 16.3 \"Specific Renal Alert Criteria and Actions and Event Follow-up\"', 'Coagulation', 'International normalized ratio (INR), activated partial thromboplastin time (APTT)', 'Pregnancy Test', 'Serum / Urine pregnancy test', '8.4.2', 'Electrocardiogram (ECG)', 'ECGs will be measured according to the assessment schedule in Table 8-1. ECGs must be', 'recorded after 10 minutes rest in the supine position to ensure a stable baseline. The preferred', 'sequence of cardiovascular data collection during study visits is ECG collection first, followed', 'by vital signs. The Fridericia QT correction formula (QTcF) should be used for clinical', 'decisions.', 'Single 12-lead ECGs will be collected using the sites own ECG machines and key parameters', 'and the original trace available within the source data.']\n\n###\n\n", "completion": "END"}